CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans

European Journal of Clinical Pharmacology

Volumn 68, Issue 3, 2012, Pages 267-271

  Maimbo, Milimo ^a,b   Kiyotani, Kazuma ^a   Mushiroda, Taisei ^a   Masimirembwa, Collen ^b   Nakamura, Yusuke ^a,c  

^a RIKEN   (Japan)

^b African Institute of Biomedical Science and Technology (AIBST)   (Zimbabwe)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

CYP2A6; CYP2B6; Efavirenz; HIV AIDS; UGT2B7; Zimbabwe

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYP2A6 GENE; CYP2B6 GENE; DRUG BLOOD LEVEL; DRUG METABOLISM; EXON; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; UGT2B7 GENE; ZIMBABWE;

ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE INHIBITORS; ZIMBABWE;

EID: 84857062673     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1118-0     Document Type: Article

References (16)

1. A Boulle G Van Cutsem K Cohen K Hilderbrand S Mathee M Abrahams E Goemaere D Coetzee G Maartens 2008 Outcomes of nevirapine and efavirenz based antiretroviral therapy when co-administered with rifampicin based anti tubercular therapy JAMA. 300 530 539 18677025 10.1001/jama.300.5.530 1:CAS:528:DC%2BD1cXps1ymurg%3D
2. C Marzolini A Telenti LA Decosterd G Greub J Biollaz T Buclin 2001 Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected Patients AIDS 15 71 5 11192870 10.1097/00002030-200101050-00011 1:CAS:528:DC%2BD3MXotlejsA%3D%3D (Pubitemid 32055781)
3. LK Shipton CW Wester S Stock N Ndwapi T Gaolathe I Thior A Avalos HJ Moffat JJ Mboya E Widenfelt M Essex MD Hughes RL Shapiro 2009 Safety and efficacy of nevirapine and efavirenz based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana Int J Tuberc Lung Dis. 13 360 6 19275797 1:STN:280:DC%2BD1M7pvFOluw%3D%3D
4. A Rivero JA Mira JA Pineda 2007 Liver toxicity induced by non nucleoside reverse transcriptase inhibitors J Antimicrob Chemother 59 342 6 17255142 10.1093/jac/dkl524 1:CAS:528:DC%2BD2sXktlKgs7w%3D (Pubitemid 47073440)
5. DW Haas HJ Ribaudo RB Kim C Tierney GR Wilkinson RM Gulick DB Clifford T Hulgan C Marzolini EP Acosta 2004 Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study AIDS 18 2391 400 15622315 1:CAS:528:DC%2BD2cXhtFGhtbvI (Pubitemid 40065906)
6. ET Ogburn DR Jones AR Masters C Xu Y Guo Z Desta 2010 Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation Drug Metab Dispos. 38 1218 1229 20335270 10.1124/dmd.109.031393 1:CAS:528:DC%2BC3cXos1Klsbc%3D
7. S Uttayamakul S Likanonsakul W Manosuthi N Wichukchinda T Kalambaheti EE Nakayama T Shioda S Khusmith 2010 Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults AIDS Res Ther 26 7 8
8. AS Bélanger P Caron M Harvey PA Zimmerman RK Mehlotra C Guillemette 2009 Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine Drug Metab Dispos. 37 1793 1796 19487252 10.1124/dmd.109.027706
9. C Nyakutira D Röshammar E Chigutsa P Chonzi M Ashton C Nhachi CM Masimirembwa 2008 High prevalence of the CYP2B6 516 G → T (*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe Eur J Clin Pharmacol 64 357 365 18057928 10.1007/s00228-007-0412-3 1:CAS:528:DC%2BD1cXisFCmt78%3D
10. T Lang K Klein J Fischer AK Nüssler P Neuhaus U Hofmann M Eichelbaum M Schwab UM Zanger 2001 Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver Pharmacogenetics. 11 399 415 11470993 10.1097/00008571-200107000-00004 1:CAS:528:DC%2BD3MXlvVynsbk%3D (Pubitemid 32656581)
11. K Kiyotani M Fujieda H Yamazaki T Shimada FP Guengerich A Parkinson K Nakagawa T Ishizaki T Kamataki 2002 Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians Drug Metab Pharmacokinet 17 482 487 15618701 10.2133/dmpk.17.482 1:CAS:528: DC%2BD3sXhtFanu7o%3D
12. RK Mehlotra MJ Bockarie PA Zimmerman 2007 Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations Eur J Clin Pharmacol 63 1 8 17115150 10.1007/s00228-006-0206-z 1:CAS:528:DC%2BD28XhtlCksb3E (Pubitemid 46025467)
13. MA Gyamfi M Fujieda K Kiyotani H Yamazaki T Kamataki 2005 High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana Eur J Clin Pharmacol 60 855 857 15660270 10.1007/s00228-004-0854-9 1:CAS:528:DC%2BD2MXhslGns74%3D (Pubitemid 40386155)
14. K Klein T Lang T Saussele E Barbosa-Sicard S Wolf-Hagen M Eichelbaum M Schwab UM Zanger 2005 Genetic variability of the CYP2B6 allele in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz Pharmacogenet Genomics 15 861 873 16272958 10.1097/01213011-200512000-00004 1:CAS:528: DC%2BD2MXhtFymtL3M (Pubitemid 41666768)
15. J Wang A Sonnerborg A Rane F Josephson S Lundgren L Stahle M Ingelman-Sundberg 2006 Identification of a novel specific CYP2B6 allele in African causing impaired metabolism of the HIV drug Efavirenz Pharmacogenet Genomics. 16 191 8 16495778 10.1097/01.fpc.0000230119.34205.8a (Pubitemid 44454868)
16. E Ngaimisi S Mugusi OM Minzi P Sasi KD Riedel A Suda N Ueda M Janabi F Mugusi WE Haefeli J Burhenne E Aklillu 2010 Long-term efavirenz autoinducation and its effect on plasma exposure in HIV patients Clin Pharmacol Ther 88 676 684 20881953 10.1038/clpt.2010.172 1:CAS:528:DC%2BC3cXhtlWmurjI